ijms-logo

Journal Browser

Journal Browser

Melatonin in Disease and Health 2.0

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: closed (30 November 2022) | Viewed by 26709

Special Issue Editor

Special Issue Information

Dear Colleagues,

Neurodegeneration, cancer, and cardiovascular diseases will be some of the main hot topics for the health care of the future.

It will be particularly important to consider the fine, basic mechanisms underlying the chronic dysfunctions towards which the human body gradually moves during the lifespan. In this regard, there are many recently published studies that emphasize the involvement of common general alterations (e.g., oxidative stress, inflammation, angiogenesis, and endothelial function and dysfunction) in the pathogenesis of most chronic diseases. Another point to consider is the progressive aging of the population and the associated increasing number of comorbidities. In this sense, one of the main actors that for years has been little studied is the microbiota present both in the intestine and in the skin, which is fundamental to maintaining a correct balance between oxidizing agents and oxidative defense. Moreover, it is also important in enabling healthy aging in the population, but can itself be the cause of dysfunction and alterations. There are, in fact, many exogenous and endogenous stimuli that can modify the composition of the microbiota, also altering the function of the organ in which it is resident. This is the case, for example, of the intestinal microbiota and the many pathologies in which it has been seen to be involved.

For all these reasons, it becomes fundamental to find a therapeutic and/or supplementation strategy that does not weigh on the already compromised functionality of organs and systems.

In this complex context, melatonin (N-acetyl-5-methoxytryptamine) has begun to be and remains the focus of new research works. As a small molecule that is ubiquitously present in all organisms, from cyanobacteria to humans, it has been investigated for its peculiar nocturnal production and its role in the regulation of circadian rhythms. It is now recognized for its pleiotropic activity.

Overall, its biosynthesis starts after the uptake of tryptophan by cells; specifically, this essential amino acid is converted to 5-hydroxytryptophan and then to 5-hydroxytryptamine (serotonin) and, ultimately, to melatonin. When it is released in the bloodstream, melatonin regulates physiological functions like circadian rhythm, sleep–wake cycle, gonadal activity, redox homeostasis, neuroprotection, immune modulation, and anticancer effects in the body. On the contrary, it is known that a decrease in melatonin secretion is related to the aging process and leads to tumorigenesis and visceral adiposity.

All these activities are carried out in two different ways: as an amphiphilic molecule, melatonin directly interacts with the intracellular components, but it also acts indirectly through the membrane receptors which are widely distributed in all eukaryotic cells.

Papers dealing with any aspects of melatonin in human health and disease, with special attention paid to new experimental therapeutic applications, will be considered for this Special Issue.

Prof. Dr. Rita Rezzani
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • health and pathology
  • oxidative stress and inflammation
  • endothelial dysfunction
  • aging and cancer
  • skin diseases
  • gastrointestinal disorders
  • neurodegenerative and cardiovascular diseases
  • microbiota composition and function
  • brain-gut axis
  • metabolic syndromes
  • sex/gender dimorphism

Related Special Issue

Published Papers (3 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

19 pages, 2336 KiB  
Article
Melatonin Is Neuroprotective in Escherichia coli Meningitis Depending on Intestinal Microbiota
by Dong Zhang, Shu Xu, Hucong Wu, Jiaqi Liu, Yiting Wang and Guoqiang Zhu
Int. J. Mol. Sci. 2023, 24(1), 298; https://doi.org/10.3390/ijms24010298 - 24 Dec 2022
Cited by 3 | Viewed by 1761
Abstract
Avian meningitis Escherichia coli (E. coli) can cause acute bacterial meningitis which threatens poultry health, causes great economic losses in the poultry industry, and has recently been speculated as a potential zoonotic pathogen. Melatonin can counteract bacterial meningitis-induced disruption of the [...] Read more.
Avian meningitis Escherichia coli (E. coli) can cause acute bacterial meningitis which threatens poultry health, causes great economic losses in the poultry industry, and has recently been speculated as a potential zoonotic pathogen. Melatonin can counteract bacterial meningitis-induced disruption of the blood–brain barrier (BBB), neuroinflammation, and reduce mortality. There are increasing data showing that melatonin’s beneficial effects on bacterial meningitis are associated with intestinal microbiota. In this study, our data showed that melatonin alleviated neurological symptoms, enhanced survival rate, protected the integrity of the BBB, reduced the bacterial load in various tissues and blood, and inhibited inflammation and neutrophil infiltration of brain tissue in an APEC TW-XM-meningitis mice model. The results of 16S rRNA showed that melatonin pretreatment significantly maintained the composition of intestinal microbiota in APEC-meningitis mice. The abundance and diversity of intestinal microbiota were disturbed in APEC TW-XM-meningitis mice, with a decreased ratio of Firmicutes to Bacteroides and an increased the abundance of Proteobacteria. Melatonin pretreatment could significantly improve the composition and abundance of harmful bacteria and alleviate the decreased abundance of beneficial bacteria. Importantly, melatonin failed to affect the meningitis neurologic symptoms caused by APEC TW-XM infection in antibiotic-pretreated mice. In conclusion, the results suggest that melatonin can effectively prevent meningitis induced by APEC TW-XM infection in mice, depending on the intestinal microbiota. This finding is helpful to further explore the specific target mechanism of melatonin-mediated intestinal microbiota in the prevention of and protection against Escherichia coli meningitis. Full article
(This article belongs to the Special Issue Melatonin in Disease and Health 2.0)
Show Figures

Figure 1

17 pages, 2466 KiB  
Article
Essential Hypertension and Oxidative Stress: Novel Future Perspectives
by Caterina Franco, Edoardo Sciatti, Gaia Favero, Francesca Bonomini, Enrico Vizzardi and Rita Rezzani
Int. J. Mol. Sci. 2022, 23(22), 14489; https://doi.org/10.3390/ijms232214489 - 21 Nov 2022
Cited by 21 | Viewed by 4793
Abstract
Among cardiovascular diseases, hypertension is one of the main risk factors predisposing to fatal complications. Oxidative stress and chronic inflammation have been identified as potentially responsible for the development of endothelial damage and vascular stiffness, two of the primum movens of hypertension and [...] Read more.
Among cardiovascular diseases, hypertension is one of the main risk factors predisposing to fatal complications. Oxidative stress and chronic inflammation have been identified as potentially responsible for the development of endothelial damage and vascular stiffness, two of the primum movens of hypertension and cardiovascular diseases. Based on these data, we conducted an open-label randomized study, first, to evaluate the endothelial damage and vascular stiffness in hypertense patients; second, to test the effect of supplementation with a physiological antioxidant (melatonin 1 mg/day for 1 year) in patients with essential hypertension vs. hypertensive controls. Twenty-three patients of either gender were enrolled and randomized 1:1 in two groups (control and supplemented group). The plasmatic total antioxidant capacity (as a marker of oxidative stress), blood pressure, arterial stiffness, and peripheral endothelial function were evaluated at the beginning of the study and after 1 year in both groups. Our results showed that arterial stiffness improved significantly (p = 0.022) in supplemented patients. The endothelial function increased too, even if not significantly (p = 0.688), after 1 year of melatonin administration. Moreover, the supplemented group showed a significative reduction in TAC levels (p = 0.041) correlated with the improvement of arterial stiffness. These data suggest that melatonin may play an important role in reducing the serum levels of TAC and, consequently, in improving arterial stiffness. Full article
(This article belongs to the Special Issue Melatonin in Disease and Health 2.0)
Show Figures

Graphical abstract

Review

Jump to: Research

25 pages, 2947 KiB  
Review
Melatonin as a Potential Approach to Anxiety Treatment
by Kristina Repova, Tomas Baka, Kristina Krajcirovicova, Peter Stanko, Silvia Aziriova, Russel J. Reiter and Fedor Simko
Int. J. Mol. Sci. 2022, 23(24), 16187; https://doi.org/10.3390/ijms232416187 - 19 Dec 2022
Cited by 11 | Viewed by 19295
Abstract
Anxiety disorders are the most common mental diseases. Anxiety and the associated physical symptoms may disturb social and occupational life and increase the risk of somatic diseases. The pathophysiology of anxiety development is complex and involves alterations in stress hormone production, neurosignaling pathways [...] Read more.
Anxiety disorders are the most common mental diseases. Anxiety and the associated physical symptoms may disturb social and occupational life and increase the risk of somatic diseases. The pathophysiology of anxiety development is complex and involves alterations in stress hormone production, neurosignaling pathways or free radical production. The various manifestations of anxiety, its complex pathophysiological background and the side effects of available treatments underlie the quest for constantly seeking therapies for these conditions. Melatonin, an indolamine produced in the pineal gland and released into the blood on a nightly basis, has been demonstrated to exert anxiolytic action in animal experiments and different clinical conditions. This hormone influences a number of physiological actions either via specific melatonin receptors or by receptor-independent pleiotropic effects. The underlying pathomechanism of melatonin’s benefit in anxiety may reside in its sympatholytic action, interaction with the renin–angiotensin and glucocorticoid systems, modulation of interneuronal signaling and its extraordinary antioxidant and radical scavenging nature. Of importance, the concentration of this indolamine is significantly higher in cerebrospinal fluid than in the blood. Thus, ensuring sufficient melatonin production by reducing light pollution, which suppresses melatonin levels, may represent an endogenous neuroprotective and anxiolytic treatment. Since melatonin is freely available, economically undemanding and has limited side effects, it may be considered an additional or alternative treatment for various conditions associated with anxiety. Full article
(This article belongs to the Special Issue Melatonin in Disease and Health 2.0)
Show Figures

Figure 1

Back to TopTop